Interventional Study for Detection of Prognosis of Blood Based Biomarkers in Intracerebral Hemorrhage

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-31

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Explore blood based biomarkers in patients with intracerebral haemorrhage \[cbc. Pt. LDH.CRP. Cholesterol. Na. K.. Mg. Urea Ca. Uric acid\]

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Spontaneous intracerebral hemorrhage (ICH) is a common subtype of stroke and accounts for nearly 10% to 30% of all strokes \[1\]. ICH posed a significant health burden in China in 2019, contributing to 25 million disability-adjusted life years (DALYs). It is associated with an early mortality rate of approximately 30-40% and has shown no reduction in prevalence in recent decades \[2\]. The higher incidence and mortality of ICH in middle-income and low-income countries may be attributed to limited public awareness regarding preventive measures, as well as challenges in accessing healthcare services \[3\]. So far, few treatment possibilities have yielded conclusive benefits. However, numerous predictors of poor outcomes after ICH have been suggested, including hematoma volume, hematoma expansion, perihematomal edema (PHE), and the presence and quantity of intraventricular hemorrhage growth \[4,5,6,7\]. Similarly, researchers continue to search for various blood-based biomarkers to guide management and predict outcomes after acute ICH \[8,9,10,11,12\]. A growing number of studies have shown that many novel biomarkers, such as C-reactive protein (CRP), S100A12, and interleukin-6, are associated with adverse outcomes in patients with ICH \[8,9,10\]. Thus, the application of blood-based biomarkers may improve risk stratification and aid clinical decisions in patients with ICH.

Therefore, in this review, we assessed the data available in the literature regarding the diagnostic and prognostic value of circulating blood biomarkers in patients with ICH. For each biomarker, we depicted the detailed characteristics in order to shed light on potential future clinical applications Intracerebral hemorrhage (ICH) is the second most common subtype of stroke and a critical disease usually leading to severe disability or death. ICH is more common in advanced age, male sex, and low- and middle-income countries. The case fatality rate of ICH is high, and only 12% to 39% of survivors can achieve long-term functional independence. Risk factors of ICH are hypertension, current smoking, excessive alcohol consumption, hypocholesterolemia, and drugs. Clinical presentation varies according to the size and location of hematoma, and intraventricular extension of hemorrhage.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intracerebral Hemorrhage

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Hemorrhage Biomarkers Detection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Young adults with intracerebral haemorrhage

Cohort prospective study for detection of blood based biomarkers of intracerebral hemorrhage in young adults.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. both sex
2. Age between 25 to 40 years old.
3. symptoms suggestive of intracerebral hemorrhage

Exclusion Criteria

1. Age group below 25 years and above 40 years
2. traumatic cerebral haemorrhage
3. extradural,subdural,subarachnoid hemorrhage
4. Hemorrhagic infarction

Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yasmin Sherif Mosabah

Resident doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yasmeen Sherif Mosabah, Resident doctor

Role: CONTACT

Phone: 01030837658

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Intracerebral hemorrhage

Identifier Type: -

Identifier Source: org_study_id